Patient data
| . | Sex . | Age . | Stage (Binet) . | Peripheral white blood cell count (per μL) . |
|---|---|---|---|---|
| CLL1 | F | 59 | C | 158 |
| CLL3 | M | 70 | C | 30 |
| CLL4 | M | 52 | A | 37 |
| CLL6 | M | 45 | A | 10 |
| CLL8 | M | 48 | A | 24 |
| CLL9 | M | 61 | A | 45 |
| CLL11 | M | 49 | A | 29 |
| CLL12 | F | 56 | A | 10 |
| CLL13 | F | 71 | A | 11 |
| CLL14 | F | 50 | A | 17 |
| CLL16 | M | 48 | C | 147 |
| CLL17 | M | 41 | C | 17 |
| CLL21 | M | 49 | A | 16 |
| . | Sex . | Age . | Stage (Binet) . | Peripheral white blood cell count (per μL) . |
|---|---|---|---|---|
| CLL1 | F | 59 | C | 158 |
| CLL3 | M | 70 | C | 30 |
| CLL4 | M | 52 | A | 37 |
| CLL6 | M | 45 | A | 10 |
| CLL8 | M | 48 | A | 24 |
| CLL9 | M | 61 | A | 45 |
| CLL11 | M | 49 | A | 29 |
| CLL12 | F | 56 | A | 10 |
| CLL13 | F | 71 | A | 11 |
| CLL14 | F | 50 | A | 17 |
| CLL16 | M | 48 | C | 147 |
| CLL17 | M | 41 | C | 17 |
| CLL21 | M | 49 | A | 16 |
Patient data including sex, age, clinical stage, and peripheral white blood cell count are shown. All patients are untreated with exception of patient CLL3 and CLL17. Patient CLL3 was treated with fludarabine for 5 months and patient CLL17 for 3 months prior to cell harvest. These 2 patients were excluded for autologous T-cell function assays (specific proliferation and cytotoxicity) after stimulation.